Epigenetic agents such as DNMT inhibitors, HDAC inhibitors, and HMT inhibitors counteract these effects by reactivating chemokines and cytokines, thereby enhancing immune infiltration and restoring immune sensitivity in HCC [196]. The gene discussed is DNMT1; the disease is hepatocellular carcinoma.